MarketCap
Facebook
X
Telegram
Avid Bioservices Cost of Revenue | CDMO
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Avid Bioservices
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 133 M | 118 M | 82.9 M | 66.6 M | 55.8 M | 46.4 M | 56.5 M | 38.3 M | 23 M | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 133 M | 23 M | 68.9 M |
Quarterly Cost of Revenue Avid Bioservices
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 35.5 M | 34.5 M | 31.4 M | 30.1 M | 33.6 M | 31.4 M | 28.2 M | 33.6 M | 27.6 M | 28.2 M | 22.4 M | 30.6 M | - | 15.6 M | 15.6 M | 14.6 M | 19.4 M | 12.8 M | 12.8 M | 15 M | 14.2 M | 11.7 M | 11.7 M | 9.84 M | 11.4 M | 11 M | 9.84 M | 9.84 M | 11.4 M | - | 16.2 M | 20.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 35.5 M | 9.84 M | 20.4 M |
Cost of Revenue of other stocks in the Biotechnology industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Amgen
AMGN
|
12 B | $ 444.7 | 1.24 % | $ 239 B |  USA |
 |
Amarin Corporation plc
AMRN
|
96 M | $ 12.13 | 2.88 % | $ 5.03 B |  Irlanda |
 |
Amneal Pharmaceuticals
AMRX
|
1.91 B | $ 21.07 | 3.39 % | $ 6.6 B | USA |
 |
Aclaris Therapeutics
ACRS
|
2.09 M | $ 3.77 | 0.4 % | $ 462 M | USA |
 |
ADMA Biologics
ADMA
|
217 M | $ 11.05 | 3.46 % | $ 2.63 B | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
71.4 M | $ 26.3 | 3.1 % | $ 3.99 B | USA |
 |
Agenus
AGEN
|
1.02 M | $ 6.19 | -2.21 % | $ 184 M | USA |
 |
Agios Pharmaceuticals
AGIO
|
6.34 M | $ 36.67 | -0.91 % | $ 2.13 B | USA |
 |
ADC Therapeutics SA
ADCT
|
5.8 M | $ 1.51 | 4.51 % | $ 192 M |  Schweiz |
 |
AbbVie
ABBV
|
18.2 B | $ 286.99 | 0.47 % | $ 508 B | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
89 M | $ 19.75 | 0.08 % | $ 3.33 B | USA |
 |
Aquestive Therapeutics
AQST
|
18.6 M | $ 3.98 | -0.63 % | $ 426 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
96.4 M | $ 1.54 | -0.32 % | $ 410 M |  Britain |
 |
BeyondSpring
BYSI
|
3.2 M | $ 0.47 | 9.77 % | $ 19.3 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
341 M | $ 72.06 | -0.76 % | $ 1.45 B | USA |
 |
Ardelyx
ARDX
|
39.5 M | $ 3.01 | -2.31 % | $ 726 M | USA |
 |
argenx SE
ARGX
|
451 M | $ 866.15 | -0.86 % | $ 53.1 B |  Niderland |
 |
Axsome Therapeutics
AXSM
|
47.5 M | $ 143.88 | -0.8 % | $ 7.16 B | USA |
 |
BioNTech SE
BNTX
|
642 M | $ 86.9 | -1.38 % | $ 21 B |  Germany |
 |
Aytu BioScience
AYTU
|
20.8 M | $ 1.93 | 1.58 % | $ 23.8 M | USA |
 |
Codexis
CDXS
|
9.34 M | $ 1.29 | 0.39 % | $ 112 M | USA |
 |
GT Biopharma
GTBP
|
57 K | $ 5.17 | -5.31 % | $ 28.5 M | USA |